EP1883412A4 - Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy - Google Patents

Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy

Info

Publication number
EP1883412A4
EP1883412A4 EP06759150A EP06759150A EP1883412A4 EP 1883412 A4 EP1883412 A4 EP 1883412A4 EP 06759150 A EP06759150 A EP 06759150A EP 06759150 A EP06759150 A EP 06759150A EP 1883412 A4 EP1883412 A4 EP 1883412A4
Authority
EP
European Patent Office
Prior art keywords
sulodexide
treatment
reducing agent
blood pressure
pressure reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06759150A
Other languages
German (de)
French (fr)
Other versions
EP1883412A1 (en
Inventor
Michael Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of EP1883412A1 publication Critical patent/EP1883412A1/en
Publication of EP1883412A4 publication Critical patent/EP1883412A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP06759150A 2005-05-05 2006-05-05 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy Withdrawn EP1883412A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67909605P 2005-05-05 2005-05-05
US73697305P 2005-11-14 2005-11-14
PCT/US2006/017403 WO2006121853A1 (en) 2005-05-05 2006-05-05 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy

Publications (2)

Publication Number Publication Date
EP1883412A1 EP1883412A1 (en) 2008-02-06
EP1883412A4 true EP1883412A4 (en) 2008-09-03

Family

ID=37396874

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06759150A Withdrawn EP1883412A4 (en) 2005-05-05 2006-05-05 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy

Country Status (6)

Country Link
EP (1) EP1883412A4 (en)
JP (1) JP2008540448A (en)
AU (1) AU2006244446A1 (en)
CA (1) CA2606880A1 (en)
IL (1) IL187142A0 (en)
WO (1) WO2006121853A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008008213A (en) 2005-12-22 2008-09-03 Neurochem Int Ltd Treatment of renal disorders, diabetic nephopathy and dyslipidemias.
CN101632686A (en) * 2008-04-04 2010-01-27 马斯特里赫特大学 Use of glycosaminoglycan for restoring glycocalyx
CN104017102B (en) * 2014-06-19 2016-02-24 深圳市海普瑞药业股份有限公司 Ethanol precipitation prepares the method for Sulodexide raw material from heparin byproduct

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093850A2 (en) * 2000-06-07 2001-12-13 Alfa Wassermann, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270846B (en) * 1993-05-10 1997-05-13 Alfa Wassermann Spa USE OF SULODEXIDE AND MEDICINAL SPECIALTIES THAT CONTAIN IT IN THE TREATMENT OF DIABETIC NEPHROPATHY.
IT1292426B1 (en) * 1997-06-27 1999-02-08 Nicox Sa NITRATED SALTS OF ACE-INHIBITORS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093850A2 (en) * 2000-06-07 2001-12-13 Alfa Wassermann, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANDIDO RICCARDO ET AL: "Treatment for diabetic nephropathy - a review of the recent patent literature.", IDRUGS : THE INVESTIGATIONAL DRUGS JOURNAL MAR 2002, vol. 5, no. 3, March 2002 (2002-03-01), pages 237 - 265, XP002486359, ISSN: 1369-7056 *
GAMBARO GIOVANNI ET AL: "Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 13, no. 6, June 2002 (2002-06-01), pages 1615 - 1625, XP002486358, ISSN: 1046-6673 *
See also references of WO2006121853A1 *

Also Published As

Publication number Publication date
CA2606880A1 (en) 2006-11-16
EP1883412A1 (en) 2008-02-06
AU2006244446A1 (en) 2006-11-16
WO2006121853A1 (en) 2006-11-16
JP2008540448A (en) 2008-11-20
IL187142A0 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
IL236831A0 (en) Mirna expression in human peripheral blood microvesicles and uses thereof
EP2043705A4 (en) System and method for use of agent in combination with subatmospheric pressure tissue treatment
IL246402A (en) Therapeutic agent for treating obesity, diabetes and diseases associated with impaired glucose tolerance
HUE064811T2 (en) Exendin for use in treating diabetes and reducing body weight
KZ24152B (en) Method of photosensitizer activation, treatment method with application of activated photosensitizer and photosensitizer application to prepare medicine
EP1799263A4 (en) Reducing er stress in the treatment of obesity and diabetes
IL207894A (en) Therapeutic combination for use in the treatment of a hyperproliferative disorder comprising trastuzumab-mcc-dmi and a chemotherapeutic agent
IL186592A0 (en) Treatment and diagnostic catheters with hydrogel electrodes
HK1158705A1 (en) Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
GB0523576D0 (en) Drug composition and its use in therapy
EP2061531A4 (en) Intravascular blood pump and catheter
PL1912650T3 (en) Use of flibanserin in the treatment of obesity
EP2059183A4 (en) Energetically activated biomedical nanotheurapeutics integrating dental and medical treatments and procedures
EP2046973A4 (en) For the identification, assessment, and treatment of patients with cancer therapy
GB0700436D0 (en) Impulse therapy for enhanced blood circulation in the body
IL190206A0 (en) Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome
IL183056A0 (en) Use of ranolazine in combination with at least one remodeling agent for revering ieft ventricular remodeling in the treatment of heart failure
HK1168283A1 (en) Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto sorcs1
EP2086506A4 (en) Preparation of heavy metal-containing nano-liposomes and their uses in medical therapy
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
EP2046313A4 (en) The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia
IL187142A0 (en) Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
GB0821839D0 (en) The use of metformin and compounds containing metformin in the treatment of diseases or conditions in patients with raised serum amyloid A
GB0700911D0 (en) Treatment of inflammation and the complement and kinin cascades in a patient, particularly in chronic ulcerous skin lesions
PT2160213E (en) Kit for the extracorporeal treatment of a biological fluid of a patient, and unit provided with said kit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 13/12 20060101ALI20080722BHEP

Ipc: A61K 45/06 20060101ALI20080722BHEP

Ipc: A61K 31/41 20060101ALI20080722BHEP

Ipc: A61K 31/40 20060101ALI20080722BHEP

Ipc: A61K 31/727 20060101ALI20080722BHEP

Ipc: A61K 31/737 20060101AFI20061201BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080731

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081030